Search

Your search keyword '"Belevich YV"' showing total 3 results
Start Over Author "Belevich YV"
3 results on '"Belevich YV"'

1. Responses of Blood System to Doxorubicin/Docetaxel Chemotherapy in Patients with Breast Cancer.

Author

Goldberg VE, Polyakova TY, Popova NO, Vysotskaya VV, Simolina EI, Dudnikova EA, Goncharova NM, Belevich YV, Grigor'ev EG, Goldberg AV, and Dygai AM

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow metabolism, Cell Lineage drug effects, Erythrocytes cytology, Female, Granulocyte Colony-Stimulating Factor metabolism, Granulocytes cytology, Humans, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Docetaxel therapeutic use, Doxorubicin therapeutic use, Erythropoiesis drug effects, Leukopoiesis drug effects
Abstract

We studied the effects of combined chemotherapy with doxorubicin/docetaxel on erythroid and granulocytic hematopoietic lineages with particular attention focused on their recovery in patients with stages III-IV breast cancer. Intensification of differentiation of erythroid and granulocytic CFU (even under conditions of their suppressed proliferation) provided the increase in the content of mature and morphologically differentiated elements in the bone marrow and peripheral blood. High proliferative activity of erythroid and granulomonocytic precursors resulted from enhanced production of hematopoiesis-stimulating activities by microenvironment elements.

Published
2019
Full Text
View/download PDF

2. Mechanisms of Granulocytopoiesis Recovery Stimulation with Filgrastim in Breast Cancer Patients Receiving Chemotherapy.

Author

Goldberg VE, Polyakova TY, Popova NO, Vysotskaya VV, Simolina EI, Dudnikova EA, Goncharova NM, Belevich YV, Tuzikova TP, Goldberg AV, Miroshnichenko LA, Udut EV, Simanina EV, Zyuz'kov GN, Zhdanov VV, and Dygai AM

Subjects
Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Female, Fluorouracil therapeutic use, Granulocyte Colony-Stimulating Factor metabolism, Humans, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Filgrastim therapeutic use, Granulocytes cytology, Granulocytes drug effects
Abstract

We studied myelotoxicity of modern schemes of chemotherapy for breast cancer (docetaxel/doxorubicin and cyclophosphamide/doxorubicin/5-fluorouracil) towards granulocytopoiesis, the mechanisms determining the differences of hematological effects of these schemes, and the efficiency of correction of the observed changes with granulocyte CSF (filgrastim). Granulocytopoiesis stimulation with filgrastim during the treatment with docetaxel/doxorubicin combination was more pronounced than during cyclophosphamide/doxorubicin/5-fluorouracil therapy. The observed differences were found at all levels of granulocyte lineage organization (central and peripheral), which is related to different effects of the cytostatic substances used in the proposed protocols on the structures controlling hemopoiesis.

Published
2018
Full Text
View/download PDF

3. Assessment of Erythroid and Granulocytic Hematopoietic Lineages in Patients with Non-Small-Cell Lung Carcinoma.

Author

Goldberg VE, Polyakova TY, Popova NO, Vysotskaya VV, Simolina EI, Belevich YV, Tuzikova TP, Goldberg AV, Zhdanov VV, Miroshnichenko LA, Udut EV, Simanina EV, Dygai AM, and Zyuz'kov GN

Subjects
Anthracyclines pharmacology, Antineoplastic Agents pharmacology, Cell Differentiation drug effects, Cisplatin pharmacology, Disaccharides pharmacology, Docetaxel, Doxorubicin pharmacology, Erythropoiesis drug effects, Granulocytes cytology, Granulocytes drug effects, Hematopoietic Stem Cells drug effects, Hematopoietic Stem Cells metabolism, Humans, Macrolides pharmacology, Nitrosourea Compounds pharmacology, Organoplatinum Compounds pharmacology, Taxoids pharmacology, Carcinoma, Non-Small-Cell Lung metabolism, Granulocytes metabolism, Lung Neoplasms metabolism
Abstract

The toxic effects of combined cisplatin/docetaxel therapy cycles on erythroid and granulocytic hematopoietic lineages as well as their intercycle recovery were examined in patients with stage III-IV non-small-cell lung carcinoma. Responsiveness of the blood system to this therapy remained at a high level. Combined therapy pronouncedly activated the key elements of the erythroid and granulocytic hematopoietic lineages leading to accumulation of immature and mature myelokaryocytes in the bone marrow, enlargement of the medullary pool of mature neutrophils, and increase in the count of medullary erythroid and granulocytic precursor cells under conditions of their accelerated maturation.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results